Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Non-invasive mechanical ventilation (NIV) has been increasingly used as a treatment of chronic hypercapnic respiratory failure. Its use in patients affected by chronic obstructive pulmonary disorders is still controversial, while most of the studies performed in restrictive thoracic disorders (RTD), and in particular in neuromuscular patients, suggested alleviation of the symptoms of chronic hypoventilation in the short term, and in two small studies survival was prolonged.
In the terminal phase of the disease, when the respiratory muscles became weaker it is very likely that the operators need to frequently adjust the level of inspiratory pressure in an attempt to guarantee an adequate tidal volume, so that alveolar hypoventilation may be avoided.
Theoretically the use of a volume assisted ventilation may overpass this problem of frequent variations of the settings, since the provision of a fixed tidal volume may always guarantee and adequate alveolar ventilation.
The primary aims of this multicenter randomized study are to evaluate the clinical efficacy, the patients' tolerance and quality of life and the frequency of changing settings in a group of patients with SLS and initial chronic respiratory failure undergoing long-term NIV with Pressure Support Ventilation or Volume Assisted Ventilation.
| Condition | Intervention | Phase |
|---|---|---|
|
Amyotrophic Lateral Sclerosis Chronic Respiratory Failure |
Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers Device: Non invasive ventilation |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Caregiver, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode |
- quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- tolerance to NIV [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- number of hours of NIV per day [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- frequency of hospital admission [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- frequency of changing the ventilator settings by the operator. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- diurnal and nocturnal gas exchange [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Pulmonary Function Tests (PFTs). [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Volume assist non-invasive ventilation
|
Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers
A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
Other Names:
Device: Non invasive ventilation
A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
Other Names:
|
|
Active Comparator: 2
Pressure Assist mode
|
Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers
A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
Other Names:
Device: Non invasive ventilation
A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
Other Names:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with the diagnosis of ALS and one of the following signs:
- Vital Capacity < 50% predicted
- A Maximal Inspiratory Pressure (MIP) < 60% predicted
- Polygraphic signs of nocturnal hypoventilation with daytime symptoms.
Exclusion Criteria:
- Life expectancy>12 months
- Any comorbidity
- Acute Respiratory Failure
Contacts and Locations| Contact: Stefano Nava, MD | 0382 592 ext 806 | snava@fsm.it |
| Contact: Franco Fanfulla, MD | 0382 592 ext 815 | ffanfulla@fsm.it |
| Italy | |
| Respiratory Unit FSM | Not yet recruiting |
| Pavia, Italy, 27100 | |
| Contact: Stefano Nava, md 0382 592 ext 806 snava@fsm.it | |
| Contact: Francesco Fanfulla, MD 0382 592 ext 815 ffanfulla@fsm.it | |
| Principal Investigator: Stefano Nava, MD | |
| Fondazione S.Maugeri | Recruiting |
| Pavia, Italy, 27100 | |
| Contact: Stefano Nava, md o3825921 snava@fsm.it | |
| Contact: Stefano Nava, md 03825921 snava@fsm.it | |
| Principal Investigator: | Stefano Nava | Fondazione Salvatore Maugeri |
| Principal Investigator: | Stefano Nava, MD | Fondazione S.maugeri |
More Information
No publications provided
| Responsible Party: | Stefano Nava, Fondazione S.Maugerii |
| ClinicalTrials.gov Identifier: | NCT00560287 History of Changes |
| Other Study ID Numbers: | 190H09, 190H09 |
| Study First Received: | November 16, 2007 |
| Last Updated: | March 26, 2010 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Fondazione Salvatore Maugeri:
|
Amyotrophic Lateral Sclerosis Non-invasive ventilation Chronic Respiratory Failure |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Sclerosis Motor Neuron Disease Respiratory Insufficiency Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Neurodegenerative Diseases |
TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Pathologic Processes Respiration Disorders Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 19, 2013